Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Ravulizumab in Trigger-associated Thrombotic Microangiopathy
jRCT2031210494Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in thrombotic microangiopathies (TMA) comparing Ravulizumab with Placebo (2 arms). Primary endpoint: Complete TMA Response at 26 Weeks. Started Jan 2022; status: completed.
02
Drugs
ravulizumab
03
Conditions
thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on jRCT2031210494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210494.